Baroreflex Activation Therapy for the Treatment of HFrEF – When CRT Is Not an Option
In this webinar, cardiologists, heart failure specialists and electrophysiologists will go through this simple implantable device that electrically stimulates the carotid baroreflex to improve symptoms of HFrEF. The panel will discuss patient indication, our latest clinical data, and incorporation into clinical practice.
Key Learning Objectives
- Review the role of the baroreflex as a primary regulator of cardiovascular function and have a better understanding of the mode of action.
- Identify the patient indication for carotid baroreceptor stimulation in heart failure with reduced ejection fraction.
- Review the long term data and experience with baroreflex activation therapy in heart failure with reduced ejection fraction.
- Get to know the device, and the implantation procedure of BAROSTIM.
- Exchange with experienced physicians that prescribe and use BAROSTIM in their hospitals.
Target Audience
- Heart Failure Specialist
- Cardiologist
- Interventional Cardiologist
- Rhythmologist
More from this programme
Part 1
Welcome and Introduction
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Introduction: BAT Mode of Action & Patient Indication for HF
Part 3
Clinical Results (Presentation of clinical data on Heart Failure as HOPE4HF & BeAT-HF study)
Part 4
Device Presentation & Implant Procedure
Part 5
Case Study: advanced HF, ventricular arrhythmias and BAROSTIM
Part 6
Summary of Baroreflex Activation Therapy for HFrEF
Faculty Biographies
Faiez Zannad
Professor Emeritus; Founder and Chairman of CVCT Société Civile
Prof Faiez Zannad was born in Monastir, Tunisia in 1951 and later moved to pursue his medical education and research in Europe. He trained in cardiology and pharmacology across institutions in France and the United Kingdom, including Nancy, Lyon, and Oxford. Over the course of his career, he has lived and worked primarily in Nancy, France, where he has held clinical, academic, and research leadership roles in cardiovascular medicine and therapeutics.
Academic History
Prof Zannad earned his MD in cardiology from the Faculté de Médecine de Nancy and further trained as a research fellow in clinical pharmacology at the Medical Research Council in Oxford. He later received a PhD in cardiovascular clinical pharmacology from the University of Lyon. During his academic training, he focused on cardiovascular pharmacology, physiology, and therapeutic innovation, laying the foundation for his lifelong work in heart failure and hypertension research.
Following…